This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American Even if you have never heard of biosimilar ...

CVS announced Tuesday it will expand its use of lower-cost biosimilars and tr | The move to prioritize biosimilars comes as ...

The FDA has approved a new biosimilar drug for inflammatory disease, based on the popular Stelara (ustekinumab). Biosimilar drugs are biologically similar, but not identical to existing biologics. The ...

Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost ...

May 5 () - CVS Health said on Tuesday it would prefer lower-cost, interchangeable biosimilars ‌over Johnson & Johnson's ...

After biosimilars launch, it can take years for them to gain a foothold. In 2023, Humira biosimilars made barely a dent in the market, and in 2024 they accounted for only about a quarter of sales, ...

Biosimilars are near-identical versions of biologic cancer drugs, available at lower costs. Germany saves hundreds of millions annually from just one biosimilar drug. Patient mistrust and policy ...

The fastest-growing area of healthcare spending is prescription drugs. Leading the way is an expensive class of medicines called biologics, which commonly cost up to $200,000 annually. There are ...

The FDA has decided that biosimilar medications must have unique naming features, distinguishing them from brand-name biologics in a move to improve patient safety, according to a STAT news report. 1.

New legislation would authorize pharmacists to substitute a biosimilar when filling a prescription, just like a generic, provided your doctor agrees.

Since his second term started, President Trump has introduced a flurry of initiatives aimed at taming the excesses of the ...